Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review

Francesco Pierantoni, Marco Maruzzo, Antonella Brunello, Benedetta Chiusole, Grazia Pusole, Elisabetta Bezzon, Umberto Basso, Vittorina Zagonel

Research output: Contribution to journalArticlepeer-review


Soft tissue sarcomas are rare neoplasms, with a high mortality rate. Few drugs are available for the treatment of patients affected by metastatic sarcomas, who still have a 5-years survival rate lower than 20%. However, some of the more recent therapies can obtain long lasting responses in a portion of patients, such as Trabectedin. We analyzed four such cases treated at our Institute after progression to an anthracycline based regimen. In each case a therapeutic pause was proposed after at least 6 months of therapy with Trabectedin and in three out of four patients a re-challenge was proposed at progression, achieving again disease control or response. In two cases oligo-progressive sites were treated with localized therapies as stereotactic radiotherapy, delaying the systemic treatment re-start. In this article the reports of the patients involved are presented with a concise review of the relevant literature. Our findings support the favorable safety profile of Trabectedin and the feasibility of drug holidays, which should be at least discussed with the patient.

Original languageEnglish
Article number553
Pages (from-to)1-7
Number of pages7
JournalFrontiers in Oncology
Publication statusPublished - 2019


Dive into the research topics of 'Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review'. Together they form a unique fingerprint.

Cite this